Compositions and methods for treating epilepsy and related disorders
The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating epilepsy, epileptic seizures and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
1. A method for treating epilepsy or seizure in a subject in need thereof, said method comprising
orally administering to said subject an induction dose of a combination of (i) a therapeutic composition comprising uncultured fecal bacteria and (ii) a cultured bacterial isolate, according to a first dosing schedule; and
subsequently orally administering to said subject a maintenance dose of said combination according to a second dosing schedule,
wherein said maintenance dose is lower than said induction dose.
2. The method of claim 1 , wherein said seizure is selected from the group consisting of focal seizure and generalized seizure.
3. The method of claim 2 , wherein said focal seizure is selected from the group consisting of simple focal seizure, complex focal seizure, and secondary generalized seizure.
4. The method of claim 2 , wherein said generalized seizure is selected from the group consisting of absence seizure, tonic seizure, atonic seizure, clonic seizure, myoclonic seizure, and tonic-clonic seizure.
5. The method of claim 1 , wherein said method reduces the overall frequency of seizures.
6. The method of claim 1 , wherein said methods prevent a relapse in seizures.
7. The method of claim 5 , wherein said method reduces said frequency by at least 10%, 20%, 30%, 50%, 60%, 70%, 80%, or 90% after 4, 8, or 12 weeks of treatment.
8. The method of claim 1 , wherein said first dosing schedule is daily or weekly.
9. The method of claim 1 , wherein said therapeutic composition is in a capsule.
10. The method of claim 1 , wherein said therapeutic composition is in a liquid, frozen, freeze-dried, spray-dried, foam-dried, lyophilized, or powder form.
11. The method of claim 9 , wherein said capsule is an enteric coated capsule, an acid-resistant, enteric-coated capsule, or an enteric coated microcapsule.
12. The method of claim 1 , wherein said subject is pretreated with an antibiotic prior to said orally administering of the induction dose of the combination.
13. The method of claim 1 , wherein said second dosing schedule is daily or weekly.
14. The method of claim 1 , wherein said induction dose comprises administering a greater number of capsules per day than said maintenance dose.
15. The method of claim 1 , wherein said subject in need thereof is deficient in one or more of Akkermansia or Parabacteroides species relative to a subject who does not have epilepsy.
16. The method of claim 1 , wherein said subject in need thereof is non-responsive to ketogenic diet (KD) therapy.
17. A method of treating epilepsy or seizure in a subject in need thereof, said method comprising
determining the relative abundance of one or more Akkermansia or Parabacteroides species in an intestine of the subject;
orally administering to said subject an induction dose of a therapeutic composition comprising a non-selected fecal microbiota if the relative abundance of the one or more Akkermansia or Parabacteroides species is less than a threshold level, wherein said induction dose is administered according to a first dosing schedule; and
subsequently orally administering to said subject a maintenance dose of said therapeutic composition according to a second dosing schedule,
wherein said maintenance dose is lower than said induction dose.
18. A method of treating epilepsy or seizure in a subject in need thereof, said method comprising
administering to said subject an induction dose of a combination of (i) a therapeutic composition comprising uncultured fecal bacteria and (ii) a cultured bacterial isolate, according to a first dosing schedule; and
subsequently administering to said subject a maintenance dose of said combination according to a second dosing schedule,
wherein said maintenance dose is lower than said induction dose, and
wherein said subject is free of gut dysbiosis immediately prior to said treating.
19. The method of claim 18 , wherein said therapeutic composition is in a capsule.
20. The method of claim 18 , wherein said composition is in a liquid, frozen, freeze-dried, spray-dried, foam-dried, lyophilized, or powder form.